FDA issues Myfortic tablets safety alert

Nov 28, 2007

The U.S. Food and Drug Administration issued a safety alert for pregnant patients using the kidney transplant drug Myfortic delayed-release tablets.

The FDA said it has been determined the medication is associated with increased risks of pregnancy loss and congenital malformations. Officials said the pregnancy category for Myfortic has been changed to Category D -- positive evidence of fetal risk.

Myfortic is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

The FDA said a transplant patient planning a pregnancy shouldn't use Myfortic unless she cannot be successfully treated with other immunosuppressant drugs.

Myfortic is manufactured by Novartis Pharmaceuticals.

Copyright 2007 by United Press International

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Cruising high seas, engineers detect fake GPS signals

15 minutes ago

Cruising the Mediterranean aboard a superyacht, a Cornell professor and grad student took their Global Positioning System (GPS) research to the high seas. For four days in late June, they tested the newest ...

The five most poisonous substances

23 minutes ago

With the announcement of an inquiry into the murder of Alexander Litvinenko, talk of poisons is back in the news. There are many articles with lists of the most poisonous substances, which are often gathered based on their acute toxicity as measured by something called LD ...

Why aren't consumers buying remanufactured products?

25 minutes ago

Firms looking to increase market share of remanufactured consumer products will have to overcome a big barrier to do so, according to a recent study from the Penn State Smeal College of Business. Findings from faculty members ...

Recommended for you

Determine patient preferences by means of conjoint analysis

8 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0